Amendments to the claims

The listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Original) A compound of formula (**I**):



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)- or -SO_2-;

X is H;

Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), (C_{0-4}-alkyl)-dichloropyridine, or CH_2NSO_2-(C_{1-4}-alkyl);

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 is H;

R^5 is -OH, or -O-C(O)R^6;

R^6 is C_{1-8}-alkyl, amino-(C_{1-8}-alkyl), (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), C_{3-6}-cycloalkyl, phenyl, benzyl, or aryl;

or a pharmaceutically acceptable salt or solvate thereof.

2. (Original) The compound of claim 1, wherein Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), or CH_2NSO_2(C_{1-4}-alkyl).

3. (Original) A compound of formula **(II)** :



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)-, or -SO_2-;

X is halogen, CN, NR_7R_8, NO_2, CH_3, or CF_3;

Z is (C_{0-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-CN, (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{0-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), (C_{0-4}-alkyl)-dichloropyridine, or (C_{0-4}-alkyl)-NSO_2(C1-4-alkyl);

W is C_{3-6}-cycloalkyl, (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-8}-alkyl)-(C_{3-6}cycloalkyl)-NR_7R_8, (C_{0-8}-alkyl)-NR_7R_8, (C_{0-4}alkyl)-CHR_9-(C_{0-4}alkyl)-NR_7R_8,

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is C_{1-8}-alkyl, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 and R^5 are independently H, C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), OH, or OC(O)R^6;

R^6 is C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), amino-(C_{1-8}-alkyl), phenyl, benzyl, or aryl;

R_7 and R_8 are each independently H, C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), phenyl, benzyl, aryl, or can be taken together with the atom connecting them to form a 3 to 7 membered heterocycloalkyl or heteroaryl ring;

R_9 is C_{1-4} alkyl, (C_{0-4}-alkyl)-aryl, (C_{0-4}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-4}alkyl)-heterocycle;R_9 is C_{1-4} alkyl, (C_{0-4}alkyl)aryl, (C_{0-4}alkyl)-(C_{3-6}cycloalkyl), (C_{0-4}alkyl)-heterocylcle;

or a pharmaceutically acceptable salt or solvate thereof.

4. (Original) The compound of claim 3, wherein W is:



5. (Original) The compound of claim 1 or 3 wherein R_1 is CH_3.

6. (Original) The compound of claim 1 or 3 wherein R_2 is CH_2CH_3, CH_3, CH_2-cyclopropyl, or cyclopentyl.

7. (Original) The compound of claim 1 or 3 wherein Y is –C(O)- or -CH_2-.

8. (Original) The compound of claim 3 wherein X is fluoro, chloro or bromo.

9. (Original) A compound of formula (**III**):



wherein:

R_1, R_2 and R_3 are independently H or C_{1-8}-alkyl, with the proviso that at least one of R_1, R_2 and R_3 is not H;

or a pharmaceutically acceptable salt or solvate thereof.

10. (Original) The compound of claim 9, wherein R_1 is H and R_2 and R_3 are both methyl.

11. (Original) An enantiomerically pure S isomer of a compound of claim 1, 3 or 9, substantially free of its R isomer, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

12. (Original) An enantiomerically pure R isomer of a compound of claim 1, 3 or 9, substantially free of its S isomer, or a pharmaceutically acceptable salt, solvate, hydrate, stereoisomer, clathrate, or prodrug thereof.

13. (Original) A compound, wherein the compound is:
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxy-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(3R)-(tert-Butoxy)-N-{3-[7-(cyclopropylcarbonylamino)-1-oxoisoindolin-2-yl]-3-(3-ethoxy-4-methoxyphenyl)propyl}carbonylamino (tert-butoxy)formate;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxyamino-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfonylamino-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[3-amino-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-ureido-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[3-dimethylamino-1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide hydrochloride;
(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfonyl-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)- Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-hydroxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(1R)-Cyclopropanecarboxylic acid {2-[2-acetoxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(3R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-methanesulfinyl-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;
(3R)-3-[4-Chloro-7-(cyclopropanecarbonyl-amino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy-4-methoxy-phenyl)-propionic acid;

(3R)-3-[4-Chloro-7-(cyclopropanecarbonyl-amino)-1-oxo-1,3-dihydro-isoindol-2-yl]-3-(3-ethoxy-4-methoxy-phenyl)-propionic acid methyl ester;

(1R)-Cyclopropanecarboxylic acid {2-[2-carbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {7-chloro-2-[2-dimethylcarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {7-chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-hydroxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1R)-Cyclopropanecarboxylic acid {2-[2-acetoxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-7-chloro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-Cyclopropanecarboxylic acid {7-chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

(1S)-Cyclopropanecarboxylic acid {7-bromo-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide;

Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-propyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

Cyclopropanecarboxylic acid {2-[2-(3,5-dichloro-pyridin-4-yl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-3-hydroxy-3-methyl-butyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1R)-Cyclopropanecarboxylic acid {2-[2-cyclopropanecarbonyloxycarbamoyl-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1R)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-isobutyryloxycarbamoyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1R)-Cyclopropanecarboxylic acid {2-[2-(2,2-dimethyl-propionyloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1R)-Cyclopropanecarboxylic acid {2-[2-(3,3-dimethyl-butyryloxycarbamoyl)-1-(3-ethoxy-4-methoxy-phenyl)-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1S)-Cyclopropanecarboxylic acid {2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-7-fluoro-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-amide

(1S)-3-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-1,1-dimethyl-urea

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-2-(4-methyl-piperazin-1-yl)-acetamide

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-

dihydro-1H-isoindol-4-yl}-2-morpholin-4-yl-acetamide; hydrochloride

(1S)-N-{7-Chloro-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1H-isoindol-4-yl}-2-dimethylamino-acetamide; hydrochloride

14. (Original) A compound of the formula:


,


,


,


,


,


,


,


,


,


,



,



,



,



,



,



,



,



,



,



,


,

,

,

,

,

,

,

,

,

,

, or

.

or a pharmaceutically acceptable salt or solvate thereof.

15. (Original) A compound of the formula:



or a pharmaceutically acceptable salt or solvate thereof.

16. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula (**I**):



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)- or -SO_2-;

X is H;

Z is (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{1-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{1-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), (C_{0-4}-alkyl)-dichloropyridine, or CH_2NSO_2-(C_{1-4}-alkyl);

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 is H;

R^5 is -OH, or -O-C(O)R^6;

R^6 is C_{1-8}-alkyl, amino-(C_{1-8}-alkyl), (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), C_{3-6}-cycloalkyl, phenyl, benzyl, or aryl;

or a pharmaceutically acceptable salt or solvate thereof.

17. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula (**II**) :



wherein:

Y is -C(O)-, -CH_2-, -CH_2C(O)-, or -SO_2-;

X is halogen, CN, NR_7R_8, NO_2, CH_3, or CF_3;

Z is (C_{0-4}-alkyl)-SO_2(C_{1-4}-alkyl), (C_{0-4}-alkyl)-CN, (C_{0-4}-alkyl)-C(O)R^3, C_{1-4}-alkyl, (C_{0-4}-alkyl)-OH, (C_{0-4}-alkyl)-O-(C_{1-4}-alkyl), (C_{0-4}-alkyl)-SO(C_{1-4}-alkyl), (C_{0-4}-alkyl)-NH_2, (C_{0-4}-alkyl)-N(C_{1-8}-alkyl)$_2$, (C_{0-4}-alkyl)-N(H)(OH), (C_{0-4}-alkyl)-dichloropyridine, or (C_{0-4}-alkyl)-NSO_2(C1-4-alkyl);

W is C_{3-6}-cycloalkyl, (C_{1-8}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-8}-alkyl)-(C_{3-6}cycloalkyl)-NR_7R_8, (C_{0-8}-alkyl)-NR_7R_8, (C_{0-4}alkyl)-CHR_9-(C_{0-4}alkyl)-NR_7R_8,

R_1 and R_2 are independently C_{1-8}-alkyl, cycloalkyl, or (C_{1-4}-alkyl)-cycloalkyl;

R^3 is C_{1-8}-alkyl, NR^4 R^5, OH, or O-(C_{1-8}-alkyl);

R^4 and R^5 are independently H, C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), OH, or OC(O)R^6;

R^6 is C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), amino-(C_{1-8}-alkyl), phenyl, benzyl, or aryl;

R_7 and R_8 are each independently H, C_{1-8}-alkyl, (C_{0-8}-alkyl)-(C_{3-6}-cycloalkyl), phenyl, benzyl, aryl, or can be taken together with the atom connecting them to form a 3 to 7 membered heterocycloalkyl or heteroaryl ring;

R_9 is C_{1-4} alkyl, (C_{0-4}-alkyl)-aryl, (C_{0-4}-alkyl)-(C_{3-6}-cycloalkyl), (C_{0-4}alkyl)-heterocycle;or a pharmaceutically acceptable salt or solvate thereof.

18. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient, or diluent and a compound of formula **(III)**:



wherein:

R_1, R_2 and R_3 are independently H or C_{1-8}-alkyl, with the proviso that at least one of R_1, R_2 and R_3 is not H;

or a pharmaceutically acceptable salt or solvate thereof.

19. (Original) The pharmaceutical composition of claim 14, 15, or 16, further comprising an additional therapeutic agent.

20. (Original) The pharmaceutical composition of claim 19, wherein the additional therapeutic agent is an anti-cancer agent or an anti-inflammatory agent.

21. (Original) The pharmaceutical composition of claim 20, wherein the anti-cancer agent is paclitaxel, cisplatin, tamoxifen, docetaxel, pirubicin, doxorubicin, irinotecan, leuprolide, bicalutamide, a goserlin implant, gemcitabine, sargramostim or a steroid.

Claims 22-45. Canceled without prejudice.